Search by Drug Name or NDC
NDC 00115-1012-08 Baclofen 20 mg/1 Details
Baclofen 20 mg/1
Baclofen is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amneal Pharmaceuticals of New York LLC. The primary component is BACLOFEN.
MedlinePlus Drug Summary
Baclofen is used to treat pain and certain types of spasticity (muscle stiffness and tightness) from multiple sclerosis, spinal cord injuries, or other spinal cord diseases. Baclofen is in a class of medications called skeletal muscle relaxants. Baclofen acts on the spinal cord nerves and decreases the number and severity of muscle spasms caused by multiple sclerosis or spinal cord conditions. It also relieves pain and improves muscle movement.
Related Packages: 00115-1012-08Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Baclofen
Product Information
NDC | 00115-1012 |
---|---|
Product ID | 0115-1012_e73c54db-d445-4784-9553-4e04fe9163ca |
Associated GPIs | 75100010000310 |
GCN Sequence Number | 004680 |
GCN Sequence Number Description | baclofen TABLET 20 MG ORAL |
HIC3 | H6H |
HIC3 Description | SKELETAL MUSCLE RELAXANTS |
GCN | 18011 |
HICL Sequence Number | 001949 |
HICL Sequence Number Description | BACLOFEN |
Brand/Generic | Generic |
Proprietary Name | Baclofen |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Baclofen |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET |
Route | ORAL |
Active Ingredient Strength | 20 |
Active Ingredient Units | mg/1 |
Substance Name | BACLOFEN |
Labeler Name | Amneal Pharmaceuticals of New York LLC |
Pharmaceutical Class | GABA A Agonists [MoA], GABA B Agonists [MoA], gamma-Aminobutyric Acid-ergic Agonist [EPC] |
DEA Schedule | n/a |
Marketing Category | ANDA |
Application Number | ANDA077971 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00115-1012-08 (00115101208)
NDC Package Code | 0115-1012-08 |
---|---|
Billing NDC | 00115101208 |
Package | 30 TABLET in 1 BOTTLE (0115-1012-08) |
Marketing Start Date | 2007-10-27 |
NDC Exclude Flag | N |
Pricing Information | N/A |